Christian is a haematologist-oncologist, having trained at the Catholic University of Louvain, Belgium.  Since December 2015, Christian he has worked as a consultant for haem-onc drug development, helping companies move forward with their projects.

Christian has more than 30 years of experience in the clinical development of NCEs in haematology-oncology, and multiple myeloma specifically. This led to the approval of several new compounds that have changed the cancer treatment paradigm.

Major oncology clinical development programmes include Vinorelbine in metastatic breast cancer and NSCLC, CPT-11 (Campto or Camptosar) in 2nd line and 1st line metastatic CRC (colorectal cancer), CPT-11 in cancer patients with liver insufficiency and CPT- 11 in metastatic gastric cancer, Taxotere in metastatic gastric cancer, Procrit in solid tumours, PTK-ZK in metastatic colorectal cancer, ASA404 in non-small cell lung cancer, Pomalidomide (Pomalyst or Imnovid) in relapsed and refractory multiple myeloma and Lenalidomide (Revlimid) in newly diagnosed multiple myeloma.

Christian has also designed several programmes, negotiated them with health authorities (FDA and EMA), ran the agreed programmes, and submitted the data for approval.  Under his supervision, 13 phase III trials and numerous phase 2 and phase 1 trials have been conducted.  This work led to 11 approvals worldwide (FDA, EMA and not including ROW). Major drugs approved include Navelbine in metastatic breast cancer, CPT-11 in first and second-line metastatic colorectal cancer, CPT-11 in liver insufficiency, Taxotere in metastatic gastric cancer, safety submission for Procrit in MBC, Pomalidomide (Pomalyst or Imnovid) in Relapsed Refractory Multiple Myeloma and Revlimid in Newly Diagnosed Multiple Myeloma.